leadf
logo-loader
viewNemaura Medical Inc

Nemaura Medical unveils Type 2 diabetes management app as companion to its SugarBEAT glucose monitor

BEAT Diabetes encourages beneficial behavioral change through a range of monitoring and coaching services

Beat diabetes app next to two people
BEAT Diabetes and the SugarBEAT monitor target the underserved $69 billion market for Type 2 diabetics and $50 billion market for pre-diabetics

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the SugarBEAT continuous glucose monitor, has launched a new app to help patients prevent and reverse Type 2 diabetes. 

The digital health offering, BEAT diabetes, encourages beneficial behavioral change through a range of monitoring and coaching services. The full range of subscription-based services includes an app that makes lifestyle recommendations based on blood glucose levels, offers one-on-one coaching and routinely measures other parameters that allow improved disease management.

“We believe that simple monitoring of glucose is not enough,” CEO Faz Chowdhury said in a statement. Patients need access to a variety of methods to better manage their glucose. The combination of our self-monitoring wearable platform with digital support and prompts, as well as one-on-one coaching through the BEAT diabetes app is designed to provide greater optionality and flexibility to both patients and payors alike.”

READ: Nemaura announces 1-for-10 reverse stock split to attract institutional investors

The new BEAT diabetes website allows individuals and corporate users to register early interest, so Nemaura can provide details about what subscription packages will be available.

Combining the app with patient coaching has been proven to enhance the impact of diabetes management, the company said. Both BEAT diabetes and the SugarBEAT monitor itself serve the underserved $69 billion market for Type 2 diabetics and $50 billion market for pre-diabetics.

The Loughborough, England company’s SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. What’s unique about SugarBEAT is its skin-patch technology, which the company said offers for painless glucose management.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Nemaura Medical Inc

Price: 3.67 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $82.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read